San Francisco – November 1, 2024 – Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering (IPO). Septerna issued and sold 18,400,000 shares priced at $18 per share, which includes the full exercise of a 30-day option for the underwriters to purchase 2,400,000 additional shares. Septerna’s common stock began trading on the Nasdaq Global Select Market on October 25, 2024, under the ticker symbol SEPN. J.P. Morgan, TD Cowen, Cantor and Wells Fargo Securities acted as the joint bookrunners for the IPO.
Partners Denny Won, Charlie Kim, Kristin VanderPas and David Peinsipp led the Cooley team that advised the underwriters.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.